Orfadin

DRUG3 trials

Sponsors

Cycle Pharmaceuticals Ltd., Sutphin Drugs

Conditions

Hereditary Tyrosinemia, Type I

Phase 1

Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1)

CompletedNCT02750345

Cycle Pharmaceuticals Ltd.Hereditary Tyrosinemia, Type I

Start: 2016-03-31End: 2016-05-31Updated: 2017-06-14

Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin

CompletedNCT02750709

Cycle Pharmaceuticals Ltd.Hereditary Tyrosinemia, Type I

Start: 2015-10-31End: 2016-01-31Updated: 2017-03-15

Unknown Phase

Bio Equivalency 20 Mgm Orfadin and 20 Mgm of Nitisonine

Sutphin DrugsHereditary Tyrosinemia, Type I

Start: 2019-11-01End: 2021-03-31Target: 4Updated: 2019-10-03